Primrose Bio

Primrose Bio develops biologics manufacturing solutions centered on Pfenex Expression Technology, a microbial protein expression platform based on Pseudomonas fluorescens. With a 20-year record spanning approved therapeutics, vaccines and more than 25 global technology transfers, the platform is designed to produce antibody fragments, peptides and other difficult-to-express proteins. The company supports projects from expression strategy and strain screening through cell bank establishment, process development, analytical methods, purification and manufacturing transfer.

Its capabilities include protein secretion, non-canonical amino acid incorporation, fermentation development and documented processes designed for scale-up using standard microbial infrastructure. Primrose Bio also offers RNA polymerases and related products, including Prima Cap AG, Prima 7 Pro, Prima Cap AU and custom RNA polymerases, as well as CRM197 in research-grade and GMP-grade forms. The platform has supported clinical and commercial programs, including production of CRM197 used in approved pneumococcal vaccines and biologics such as Rylaze and teriparatide.

Primrose Bio is based in San Diego, California, and provides project consultations and quotes